Q-omics provides the consensus-scored NOD1 profile across patient tissues and cancer cell-line models. NOD1 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, NOD1 is differentially expressed in 15, with the highest sampling consensus in THCA. Additionally, NOD1 RNA expression shows 20,415 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight LUAD, THCA, and UVM as cancer lineages where NOD1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NOD1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NOD1 survival associations across molecular data types. NOD1 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (11) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NOD1 RNA expression–survival associations across cancer types. High NOD1 expression shows unfavorable associations in CESC, LGG and BLCA, but favorable associations in LUAD, MESO and THCA. The LUAD Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUAD as the clearest survival context for NOD1 RNA expression.
This table summarizes NOD1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 2. The strongest signals are observed in THCA for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for NOD1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NOD1 shows lower tumor expression in LUSC and higher tumor expression in THCA, HNSC, KIRC, COAD and LIHC. The THCA box plot shows higher NOD1 RNA expression in tumor versus normal tissue (log2 FC = +2.745, t-test p < 0.001).
This table shows molecular features associated with NOD1 in patient tissues and cancer cell lines. In patient samples, NOD1 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, NOD1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and CNS.
